Impax Laboratories — Merger or Acquisition (October 2017)
43 slides from Impax Laboratories's merger presentation, Oct 17, 2017
Slide 1: A Strategic Combination for Long-Term Growth
A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Impax Laboratories, Inc. Commission F
Slide 2: Additional Information and Where to Find It
Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the proposed transaction bet
Slide 3: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders Cautionary Note Regarding Forward-Looking Statements This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking s
Slide 4: Agenda
Agenda TRANSACTION OVERVIEW & RATIONALE Paul Bisaro – Impax President & CEO COMBINED R&D & OPERATIONS Chintu Patel – Amneal Founder & Co-CEO AMNEAL OVERVIEW & COMMERCIAL OPERATIONS Chirag Patel – Amneal Founder & Co-CEO COMBINED FINANCIAL PROFILE Bryan Reasons – Impax CFO 1 2 3 4 5 CLOSING REMARKS P
Slide 5: Transaction Overview & Rationale
Transaction Overview & Rationale 1 Paul BISARO Impax President & CEO
Slide 6: A Strategic Combination for Long-Term Growth
A Strategic Combination for Long-Term Growth Per Last Twelve Months IMS Gross Revenues as of June 2017. Includes expected Year 1 run-rate synergies. See slide 20 for detail. In addition to the previously announced Impax standalone cost savings initiatives. Expanded Portfolio to Drive Growth Creates
Slide 7: Combination Fuels Long-Term Growth
Combination Fuels Long-Term Growth Estimated Revenue ($billions) Estimated Adjusted EBITDA(1) ($billions) Double-Digit Revenue & Adjusted EBITDA Growth Projected Over Next 3 Years Driven by a Diversified Portfolio of Generic Products Filed at FDA 2017E includes expected Year 1 run-rate synergies. 20
Slide 8: Transaction Overview & Terms; NewCo Leadership
NewCo leadership Chirag Patel and Chintu Patel will be Co-Chairmen of the Board Paul Bisaro will be CEO Bryan Reasons will be CFO NewCo Board of Directors Amneal Holdings will nominate six Board members, with Impax nominating five Current Impax Chairman Bob Burr to be lead outside director Amneal Ho
Slide 9: Transaction Timeline
Transaction Timeline Transaction timeline post-announcement: FTC / Hart-Scott-Rodino filings Minimal overlap of existing generic products Complete pre-close integration planning Estimated transaction close – First Half 2018 Timeline
Slide 10: Poised for Success in Evolving Market Dynamics
Poised for Success in Evolving Market Dynamics Filed generic pipeline contains industry leading, high-value product opportunities(1) across multiple dosage forms Fully diversified, cost efficient manufacturing and development capability provides access to high-value generic product opportunities Pos
Slide 11: Amneal Overview & Commercial Operations
Amneal Overview & Commercial Operations 2 Amneal Founder & Co-CEO PATEL Chirag
Slide 12: Amneal Overview
Amneal Overview Founded by Chirag Patel and Chintu Patel in 2002 Built on a unique culture driven by a passion for growth, entrepreneurship and quality U.S. focused with commercial presence in U.K. & Germany ~5,100 total employees Differentiated pipeline and robust organic R&D platform focused on co
Slide 13: Augments Portfolio & Pipeline
Augments Portfolio & Pipeline Expands combined generic portfolio to ~165 marketed generic product families(1) and generic pipeline to ~150 ANDAs filed(1) Accelerates Amneal’s entry into specialty pharmaceuticals and bolsters Impax’s generic pipeline Complements Amneal’s capabilities on multiple dosa
Slide 14: Enhances Commercial Position
Enhances Commercial Position #1 or #2 position in ~50% of commercial portfolio(1) Provides greater revenue diversification Top 5 generic product net revenue contribution ~25%(2) Opportunity to further capture long-term benefits of NewCo development engine NewCo has invested >$1 billion in R&D over t
Slide 15: Combined R&D and Operations
Combined R&D and Operations 3 Amneal Founder & Co-CEO PATEL Chintu
Slide 16: Operational Excellence Accomplished
Operational Excellence Accomplished Research and Development capabilities in the U.S., India and Ireland 7 R&D Centers co-located within global manufacturing footprint State-of-the-art manufacturing infrastructure in place: Cost efficient sites in India and the U.S., complemented by high-end manufac
Slide 17: Diversified, High-Value Combined Pipeline
Diversified, High-Value Combined Pipeline ~315 total projects in the combined pipeline, of which ~50%+ are high value opportunities(1) Expected annual pro forma combined R&D investment: ~10% of revenues COMBINED HISTORICAL ANDA FILINGS BY YEAR AND TYPE Data as of September 30, 2017. High value oppor
Slide 18: Diverse and Expansive Manufacturing Technology Capabilities
Diverse and Expansive Manufacturing Technology Capabilities INDIA LIQUID / TOPICAL TRANSDERMAL RESPIRATORY STERILE / ASEPTIC / SOD API HAYWARD, CA, BROOKHAVEN & HAUPPAUGE, NY BRANCHBURG & PISCATAWAY, NJ PISCATAWAY, NJ CASHEL, IRELAND AHMEDABAD & HYDERABAD, INDIA VIZAG & DEHEJ, INDIA Solutions, Suspe
Slide 19: Combined Financial Profile
Combined Financial Profile 4 Impax CFO REASONS Bryan
Slide 20: Financially Compelling Combination
Financially Compelling Combination Impax reaffirms standalone 2017E financial guidance NewCo expected to generate pro forma 2017E adjusted EBITDA of ~$600-$650 million(1) NewCo expected to generate pro forma 2018E adjusted EBITDA of ~$700-$750 million(1) Accretive to Impax’s adjusted EPS in the firs
Slide 21: Fully Committed Financing in Place at Signing
Expected interest rate of LIBOR + 350(1) All debt financed with no primary equity financing Projected strong adjusted EBITDA growth and free cash flow will enable deleveraging Expected net leverage at close of ~4.0x trailing 12 months pro forma adjusted EBITDA Combined balance sheet and strong cash
Slide 22: Closing Remarks
Paul BISARO Impax President & CEO Closing Remarks 5
Slide 23: A Strategic Combination for Long-Term Growth
A Strategic Combination for Long-Term Growth Per Last Twelve Months IMS Gross Revenues as of June 2017. Includes expected Year 1 run-rate synergies. See slide 20 for detail. In addition to the previously announced Impax standalone cost savings initiatives. Expanded Portfolio to Drive Growth Creates
Slide 24: Q & A
Q & A
Slide 25: Appendix: Combined Company Information
APPENDIX: COMBINED COMPANY INFORMATION
Slide 26: Pro Forma Capitalization Table
Pro Forma Capitalization Table ($ in millions) Impax cash balance as of 6/30/2017. Assumes 232 million shares issued to Amneal and closing share price of $19.95 for IPXL as of October 16, 2017. Includes expected Year 1 run-rate synergies. See slide 20 for detail.
Slide 27: Industry-Leading Growth
Industry-Leading Growth 2017E-2020E Revenue Growth 2017E-2020E EBITDA Growth Source: Peer group projections based on Factset consensus estimates as of September 25, 2017.
Slide 28: Tangible Benefits from Increased Scale
Tangible Benefits from Increased Scale Broader product portfolio and dosage form capabilities improve selling opportunities Leverage both companies’ strong relationships with customers Source: IMS Health. Pro forma for Fresenius’s acquisition of Akorn.
Slide 29: Comprehensive Suite of Dosage Form Capabilities
Comprehensive Suite of Dosage Form Capabilities Source: Competitive intelligence based on publicly available information. Full Suite of Capabilities in Generics = No Major Investment Anticipated Going Forward IR / ER Solids Injectables Oral Liquids Nasal Sprays Respiratory Ophthalmics Patches Topica
Slide 30: Appendix: Amneal
APPENDIX: AMNEAL
Slide 31: Revenue Growing Through New Launches
Revenue Growing Through New Launches New launches in 2015 - 2017 more than offset base business decline For the LTM 6/30/17 period, products launched in 2015 and later contributed ~43% of total revenue Revenue by Product Launch Vintage: LTM 6/30/17 ($ Millions) (1) Includes new product royalties.
Slide 32: Strong Quality Systems & Track Record
Strong Quality Systems & Track Record High quality product filings Strong quality systems supporting all aspects of development, analytical testing and manufacturing Solid compliance record year-after-year Ability to flexibly respond and adapt to FDA’s new systems and procedures Includes two inspect
Slide 33: Broad Capabilities Across Dosage Forms
Broad Capabilities Across Dosage Forms ORAL SOLIDS & LIQUIDS • IR / ER tablets • Hard Gelatin Capsules • Softgel Capsules • Hormonals • Controlled Substances • Suspensions / Solutions STERILE ASEPTICS • General Injectables • Oncology Injectables • Ophthalmics • Otics COMPLEX INJECTABLES • Peptides •
Slide 34: History of Strong Financial Growth
History of Strong Financial Growth Robust double-digit top-line growth driven by increasing market share in existing franchises and new product launches Despite higher R&D to support pipeline investments, adjusted EBITDA is projected to continue growing significantly Historical Revenue ($ millions)
Slide 35: Amneal Selected Financial Data
Amneal Selected Financial Data ($ in millions) Note: The financial information with respect to Amneal included herein has been derived from Amneal's historical financial statements, which were prepared and audited in accordance with U.S. GAAP and AICPA standards, but not in accordance with PCAOB sta
Slide 36: Amneal Selected Financial Data (cont'd)
Amneal Selected Financial Data (cont’d) ($ in millions) Note: The financial information with respect to Amneal included herein has been derived from Amneal's historical financial statements, which were prepared and audited in accordance with U.S. GAAP and AICPA standards, but not in accordance with
Slide 37: Amneal Non-GAAP Financial Measures
Amneal Non-GAAP Financial Measures ($ in millions) In 2016, Amneal entered into an agreement with a former development partner to settle a contract dispute. The total amount of the settlement paid by Amneal was $2.8 million. Reflects the impairment of a product purchased in 2013 based on an unfavora
Slide 38: AP ; AX
aa @ AP ; AX P aa | _——_ \ \
Slide 39: Impax Overview
Impax Overview Founded in 1994 U.S. focused with generic and specialty branded products ~1,400 total employees Generics business targets high-value solid oral and alternative dosage form ANDAs that are difficult to develop 20 products on file and 22 products in-development 74% of filed and in-develo
Slide 40: Strong Diversified Generic Platform
Strong Diversified Generic Platform Over two decades of experience in difficult to formulate generics Robust R&D infrastructure with a strong track record of success Diversified portfolio of ~74 commercial products with a mix of solid oral and alternate dosage forms Pipeline of ~40 filed and in deve
Slide 41: Driving Growth with Specialty Brands
Driving Growth with Specialty Brands Neurology-focused, specialty pharmaceutical company Rytary ER Capsules approved for treatment of Parkinson's disease, Post-encephalitic parkinsonism, and Parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication Approved in January
Slide 42: Impax Financial Profile
Impax Financial Profile Top-line growth driven by acquisitions and increasing generic and specialty product market share in existing franchises and new product launches Significant investments in R&D and Specialty Pharma sales and marketing impacted adjusted EBITDA Historical Revenue ($ millions) Hi
Slide 43: Impax Non-GAAP Financial Measures
Impax Non-GAAP Financial Measures ($ in millions)
Impax Laboratories — Merger or Acquisition (October 2017) on 6ix